1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

FDA Approves Mylan’s Humira Biosimilar

Hulio Version Of Adalimumab Will Have To Wait Three Years To Launch

 
• By Dave Wallace

Mylan’s Hulio has become the sixth biosimilar version of Humira to be approved by the US FDA. However, all of these adalimumab biosimilars face a wait until 2023 before they can enter the market.

FDA
The FDA has approved the sixth biosimilar version of Humira • Source: Shutterstock

Mylan’s Hulio (adalimumab-fkjp) has become the sixth biosimilar rival to Humira to be approved by the US Food and Drug Administration. However, like all other biosimilar versions of Humira to be approved so far in the US, it faces a wait until 2023 to enter the market under the terms of a settlement agreement with originator AbbVie.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Glenmark’s UK Dapagliflozin Blocked On Appeal After Teva Readied Launch

 
• By Dean Rudge

Glenmark’s advantage for its UK generic version of AstraZeneca’s Forxiga (dapagliflozin) has quickly been snuffed out, after the originator won on appeal its request for injunctive relief.

How To Make The Most Of Your GGB Awards Entries

 
• By Dave Wallace

With the Global Generics & Biosimilars Awards 2025 taking place in Frankfurt this October, we bring you five key pieces of guidance to help ensure that your entries stand out from the competition.

Denosumab Race Heats Up In Europe With Eight More Nods

 
• By Dave Wallace

Denosumab competition is heating up in Europe, with four more companies this month gaining EMA endorsements for their Prolia and Xgeva biosimilar rivals.